PONS

PONS is disrupting the $100B clinical trial and biomarker industry by converting any mobile ultrasound into a powerful data source. Currently the healthcare system is limited by some major blind spots: 90% of clinical drug development fails, and we fail to collect high-quality, large-scale data on early-stage disease. PONS is solving this problem by converting any mobile ultrasound with AI into a powerful high-quality data source. PONS takes point-of-care ultrasound beyond imaging and turns it into a data engine. This ensures that capturing of data on healthy samples, as well as those in early- and later-stage disease can be captured and utilized. Imagine pharmacies and retail stores becoming mini-imaging hubs. Using PONS’s AI-powered pods, rich data can be gathered that fuels drug development, personalized medicine and accelerates the timeline for life-saving treatments.